Anti Hair Loss Powder 99 % Purity Setipiprant CAS NO.866460-33-5

Hubei Langyou International Trading Co., Ltd is a renowned pharmaceutical manufacturer. We specializing in the production of research and development of pharmaceutical intermediates, this kind of products with high quality price concessions, welcomed the new and old customers advisory purchase, companies invest large fund and brain research fine chemical r&d department,biochemical,  pharmaceutical and intermediate products to meet the demand of the market. High level research team,advanced equipment and good scientific atmosphere ensure the quality .

1.Reasonable and competitive price. Provide the best and professional service.Provide the best and professional service is our purpose.

2. Reliable shipping way.Door to door service, guarantee 100% delivery for you.

We have our own shipping agent in each country,we have special lines to your country, you no need do anything.

Will finish all the customs clearance at our side, customers are without any customs issues,door to door delivery.

3.To below countries, we are very  familiar and regular.

UK,USA,Canada,Russia,Ukraine,Kazakhstan,Belarus,Germany,Poland,Sweden,the Netherlands, Australia,Spain,Mexico,Poland  and so on. All are without problems.

Anti Hair Loss Powder 99 % Purity Setipiprant CAS 866460-33-5

setipiprant  Setipiprant

CAS No.866460-33-5

Molecular Formula C24h19fn2o3

Molecular Weight 402.42g/Mol

Colour: white

Purity: 99.5%

Application Anti-Hair Loss,Baldness

PackAge: 1kg/aluminium foil bag or According to customer requirements for packaging

Transport Package 100g, 1kg, 25kg

Most Safe Solution For Hair Loss Treatments Setipiprant Europe Fast Delivery CAS: 866460-33-5

What is Setipiprant

Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.

A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.

Application

1. Increase cellular proliferation of outer root sheeth cells.

2. Increase hair diameter and hair density.

3. Increase the percentage of hair in the anagen phase.

4. Exert no negative effect on body hormone levels.

5. Provide equivalent or better net growth than Finasteride.